NEW YORK (GenomeWeb News) – Bruker today announced it has licensed intellectual property from the Erasmus Medical Center for the rapid testing of beta-lactamase activity using MALDI-TOF technology.

The method being licensed is compatible with the Bruker MALDI Biotyper system, which uses MALDI-TOF mass spectrometry for identifying microorganisms, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.